OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

Rhea-AI Summary

OrthoPediatrics (NASDAQ: KIDS) announced record preliminary unaudited revenue for 2024, reaching $204.7 million, a 38% increase from 2023's $148.7 million. The company's domestic revenue grew 45% to $161.1 million, while international revenue increased 16% to $43.6 million.

Fourth quarter 2024 revenue reached $52.7 million, up 40% year-over-year, with domestic revenue growing 52% to $42.9 million and international revenue rising 5% to $9.8 million. The company helped over 34,000 children in Q4 2024, surpassing 1.1 million children helped since inception.

For 2025, OrthoPediatrics projects revenue between $235-242 million (15-18% growth), with expected annual set deployment of $15 million and adjusted EBITDA of $15-17 million. The company highlighted strong performance in Trauma and Deformity, Scoliosis, and specialty bracing businesses.

Positive

• Record revenue of $204.7M in 2024, up 38% YoY
• Strong domestic revenue growth of 45% in 2024
• Q4 2024 revenue increased 40% to $52.7M
• Projected 15-18% revenue growth for 2025
• Expected adjusted EBITDA of $15-17M for 2025

Negative

• International revenue growth slower at 16% compared to domestic growth
• Q4 international revenue growth slowed to 5%

Insights

Financial Analyst

OrthoPediatrics' preliminary 2024 results showcase remarkable financial performance with record revenue of $204.7 million, representing 38% YoY growth. The domestic market led growth at 45%, while international revenues grew 16%. The Q4 performance was particularly strong, with 40% growth to $52.7 million.

The 2025 guidance of $235-242 million in revenue (15-18% growth) and $15-17 million in adjusted EBITDA signals continued momentum. The $15 million planned set deployment indicates strategic investment in growth infrastructure. The specialty bracing division (OPSB) emerges as a capital-efficient growth driver with significant scaling potential.

The company's market position in pediatric orthopedics continues to strengthen, evidenced by treating over 34,000 children in Q4 alone. This expanding patient base, combined with robust domestic growth, suggests effective market penetration and execution of strategic initiatives.

Medical Research Analyst

The achievement of treating 1.1 million children since inception demonstrates OrthoPediatrics' significant market presence in pediatric orthopedics. The strong performance in both Trauma and Deformity and Scoliosis segments indicates successful product adoption and clinical acceptance. The specialty bracing business (OPSB) represents a strategic expansion that addresses a critical need in pediatric orthopedic care.

The 52% domestic growth in Q4 suggests increasing market penetration and physician preference for OrthoPediatrics' solutions. This growth trajectory, combined with international expansion opportunities, positions the company well for sustained clinical impact. The continued investment in set deployment ensures broader accessibility of their specialized pediatric orthopedic solutions.

Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year
Initiates guidance for record adjusted EBITDA in 2025

WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December 31, 2024, issued 2025 financial guidance and provided business updates.

2024 Business and Financial Highlights:

• Helped over 34,000 children in the fourth quarter 2024, the Company has now helped over 1.1 million children since inception
• Generated record preliminary unaudited full year 2024 net revenue of $204.7 million, representing growth of 38% compared to $148.7 million in 2023. Preliminary full year domestic net revenue is expected to be $161.1 million, representing 45% annual growth and international net revenue is expected to be $43.6 million, representing 16% annual growth
• Generated preliminary unaudited fourth quarter 2024 net revenue of $52.7 million, representing growth of 40% compared to $37.6 million in the fourth quarter of 2023. Preliminary domestic fourth quarter net revenue is expected to be $42.9 million, representing 52% growth compared to the prior year period, and international net revenue is expected to be $9.8 million, representing 5% growth compared to the prior year period
  

2025 Financial Guidance
OrthoPediatrics projects 2025 revenue to be in the range of $235 million to $242 million, representing 15% to 18% growth compared to full year 2024 preliminary unaudited net revenue. The Company also expects its annual set deployment to be approximately $15 million and expects to generate between $15 million to $17 million of adjusted EBITDA for the full year 2025.

“Throughout 2024 we continued to deliver strong results, advance our strategic initiatives, and grow our market share within pediatric orthopedics. Our Trauma and Deformity and Scoliosis businesses continue to execute and contribute to our overall growth as we drove topline revenue and significantly increased profitability,” commented David Bailey, President & CEO of OrthoPediatrics. “We are extremely pleased with the specialty bracing (OPSB) business performance. It has proven to be a tremendous market opportunity and provided an important strategic catalyst to further support our current customers. We are only beginning to scratch the surface of the potential for this business as a capital efficient top and bottom line driver we will continue to expand and scale over the coming years. As we look ahead, we are confident we have the right growth drivers in place to execute against our long-term outlook and deliver results all while we continue to make an impact for children.”

The Company plans to release its fourth quarter and full year 2024 financial results and provide additional commentary on its financial outlook in early March. The quarterly and annual preliminary unaudited net revenue estimates for 2024 included in this press release are prior to the completion of review and audit procedures by the Company’s independent registered public accounting firm and are therefore subject to adjustment.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential,” "objective," "would" and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and the other risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 8, 2024, as updated and supplemented by our other SEC reports filed from time to time, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements;. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures such as Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense, provision for income taxes (benefit), depreciation and amortization, tradename impairment, stock-based compensation expense, fair value adjustment of contingent consideration, acquisition related costs, nonrecurring PEGA conversion fees, Midcap financing termination loss, and the cost of minimum purchase commitments. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

The estimated Adjusted EBITDA amounts included herein are preliminary and reconciliations cannot be produced at this time without unreasonable effort. The Company expects to provide a reconciliation of Adjusted EBITDA to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2024 financial results.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about OrthoPediatrics’ Specialty Bracing portfolio, please visit https://opsb.com/.

Investor Contact
Philip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406

FAQ

What was OrthoPediatrics (KIDS) total revenue for 2024?

OrthoPediatrics achieved record preliminary unaudited revenue of $204.7 million for full year 2024, representing 38% growth compared to 2023.

How much did OrthoPediatrics (KIDS) domestic revenue grow in 2024?

OrthoPediatrics' domestic revenue grew 45% to $161.1 million in 2024.

What is OrthoPediatrics (KIDS) revenue guidance for 2025?

The company projects 2025 revenue to be between $235 million and $242 million, representing 15-18% growth compared to 2024.

What was OrthoPediatrics (KIDS) Q4 2024 revenue performance?

Q4 2024 revenue was $52.7 million, representing 40% growth compared to Q4 2023.

What is OrthoPediatrics (KIDS) projected adjusted EBITDA for 2025?

The company expects to generate between $15 million to $17 million of adjusted EBITDA for full year 2025.